A Prospective, Single-Arm, Multicenter Clinical Study of High-Risk Localized and Locally Advanced Renal Clear Cell Carcinoma

Conditions

• Urologic Neoplasms

Interventions

• DRUG: Iparomlimab and Tuvonralimab in combination with Lenvatinib

Sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Collaborators

• [object Object]
• [object Object]